Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer

Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but the reported efficacy of this regimen remained inconsistent. In order to clarify the survival benefit of this regimen, a meta-analysis was pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiantang, Fu, Fangmeng, Lin, Yuxiang, Chen, Yazhen, Lu, Minjun, Chen, Minyan, Yang, Peidong, Huang, Meng, Wang, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655315/
https://www.ncbi.nlm.nih.gov/pubmed/29113420
http://dx.doi.org/10.18632/oncotarget.20386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655315/
https://www.ncbi.nlm.nih.gov/pubmed/29113420
http://dx.doi.org/10.18632/oncotarget.20386

Ejemplares similares